Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BMRN, GENZ Phase III Aldurazyme data

BioMarin (BMRN; SWX:BMRN) and partner Genzyme (GENZ) reported six-month extension data from a previously reported Phase III trial in 45 patients with

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE